Associations of meningioma molecular subgroup and tumor recurrence

Sadeleştirilmiş öğe sayfası
dc.contributor.authorYoungblood, Mark W.
dc.contributor.authorMiyagishima, Danielle F.
dc.contributor.authorJin, Lan
dc.contributor.authorGupte, Trisha
dc.contributor.authorLi, Chang
dc.contributor.authorDuran, Daniel
dc.contributor.authorMontejo, Julio D.
dc.contributor.authorZhao, Amy
dc.contributor.authorSheth, Amar
dc.contributor.authorTyrtova, Evgeniya
dc.contributor.authorOzduman, Koray
dc.contributor.authorIacoangeli, Francesco
dc.contributor.authorPeyre, Matthieu
dc.contributor.authorBoetto, Julien
dc.contributor.authorPease, Matthew
dc.contributor.authorAvsar, Timucin
dc.contributor.authorHuttner, Anita
dc.contributor.authorBilguvar, Kaya
dc.contributor.authorKilic, Turker
dc.contributor.authorPamir, M. Necmettin
dc.contributor.authorAmankulor, Nduka
dc.contributor.authorKalamarides, Michel
dc.contributor.authorErson-Omay, E. Zeynep
dc.contributor.authorGunel, Murat
dc.contributor.authorMoliterno, Jennifer
dc.date.accessioned2023-02-21T12:41:55Z
dc.date.available2023-02-21T12:41:55Z
dc.date.issued2021-01-01
dc.description.abstractBackground. We and others have identified mutually exclusive molecular subgroups of meningiomas
dc.description.abstracthowever, the implications of this classification for clinical prognostication remain unclear. Integrated genomic and epigenomic analyses implicate unique oncogenic processes associated with each subgroup, suggesting the potential for divergent clinical courses. The aim of this study was to understand the associated clinical outcomes of each subgroup, as this could optimize treatment for patients. Methods. We analyzed outcome data for 469 meningiomas of known molecular subgroup, including extent of resection, postoperative radiation, surveillance imaging, and time to recurrence, when applicable. Statistical relationships between outcome variables and subgroup were assessed. Features previously associated with recurrence were further investigated after stratification by subgroup. We used Kaplan-Meier analyses to compare progression-free survival, and identified factors significantly associated with recurrence using Cox proportional hazards modeling. Results. Meningioma molecular subgroups exhibited divergent clinical courses at 2 years of follow-up, with several aggressive subgroups (NF2, PI3K, HH, tumor necrosis factor receptor-associated factor 7 {[}TRAF7]) recurring at an average rate of 22 times higher than others (KLF4, POLR2A, SMARCB1). PI3K-activated tumors recurred earlier than other subgroups but had intermediate long-term outcome. Among low-grade tumors, HH and TRAF7 meningiomas exhibited elevated recurrence compared with other subgroups. Recurrence of NF2 tumors was associated with male sex, high grade, and elevated Ki-67. Multivariate analysis identified molecular subgroup as an independent predictor of recurrence, along with grade and previous recurrence. Conclusion. We describe distinct clinical outcomes and recurrence rates associated with meningioma molecular subgroups. Our findings emphasize the importance of genomic characterization to guide postoperative management decisions for meningiomas.
dc.description.issue5
dc.description.issueMAY
dc.description.pages783-794
dc.description.volume23
dc.identifier.doi10.1093/neuonc/noaa226
dc.identifier.urihttps://hdl.handle.net/11443/2766
dc.identifier.urihttp://dx.doi.org/10.1093/neuonc/noaa226
dc.identifier.wosWOS:000698647000012
dc.publisherOXFORD UNIV PRESS INC
dc.relation.ispartofNEURO-ONCOLOGY
dc.subjectmeningioma genomics
dc.subjectmolecular subgroups
dc.subjectprecision medicine
dc.subjecttumor prognosis
dc.titleAssociations of meningioma molecular subgroup and tumor recurrence
dc.typeArticle
Dosyalar
Orijinal seri
Şimdi gösteriliyor 1 - 1 / 1
thumbnail.default.alt
Ad:
Associations of meningioma molecular subgroup and tumor recurrence.pdf
Boyut:
1.83 MB
Format:
Adobe Portable Document Format
Açıklama
İndir
Koleksiyonlar
WOS